NCT05911295 2026-04-07
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
Seagen Inc.
Phase 3 Active not recruiting
Clinical Trials
6 trialsNCT06003231 2026-04-07
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
Seagen Inc.
Phase 2 Active not recruiting
NCT06966453 2026-04-07
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
Pfizer
Phase 1/2 Recruiting
NCT07509424 2026-04-03
Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Not yet recruiting
NCT07507526 2026-04-02
DTP-HER2
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT07490990 2026-03-24
A Real-World, Single-Arm Study Protocol of Disitamab Vedotin in Combination With Immunotherapy and Multimodal Radiation Therapy for HER2-Positive Advanced Gastric Cancer: After Second-Line Treatment Failure
West China Hospital
Not yet recruiting